Accordingly, the first-in-class ATX inhibitor GLPG1690 developed by Galapagos (Figure 1) [23] is currently in advanced clinical trials for the treatment of idiopathic pulmonary fibrosis patients (NCT03733444). Here, ENPP2 is linked to idiopathic pulmonary fibrosis.